Biotechnology News
Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.
Bench International Enters Into Ground Breaking Strategic Alliance with Ashton Tweed
First of Its Kind Alliance Extends Mutual Service Offerings to Better Serve Clients - January 03, 2024 - Bench International
Huntington Study Group and Roche Collaborate on GENERATION HD2 Study
The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are... - December 13, 2023 - Huntington Study Group
Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction
Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and... - December 13, 2023 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Selected as a Participant in the 2023 H7 BioCapital Accelerator Program
Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform... - December 13, 2023 - Microvascular Therapeutics, Inc.
Creative Diagnostics Announces New Test Reagents for Dapsone
Creative Diagnostics has announced the launch of a range of new reagents for the analysis of Dapsone in food. - December 13, 2023 - Creative Diagnostics
Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications
Creative Diagnostics has launched a portfolio of Macrophage Migration Inhibitory Factor (MIF) reagents for researchers. - December 13, 2023 - Creative Diagnostics
Booth Unveiling Soon: Creative Biolabs and Ingenious Antibody Products at AET US 2023
Creative Biolabs highlights its participation in the upcoming Antibody Engineering and Therapeutics US 2023 conference, taking place from December 13–16, 2023. The event will be held in San Diego. - December 07, 2023 - Creative Biolabs
QuBind.com Makes Major Strides in T-Cell Immunotherapy with Revolutionary AI Innovation
In just 18 months, the young startup QuBind.com has achieved a remarkable breakthrough in T-cell immunotherapy, developing an advanced AI stack that is set to revolutionize personalized medicine. This significant milestone, reached with predominantly bootstrap funding, support from friends, family, and a strategic investment from a handful general partners in the PE sector, underscores the company's innovative spirit and scientific prowess. - December 05, 2023 - QuBind Technologies Corp
San Juan Regional Medical Center Introduces Endolumik’s Novel Fluorescent Device to New Mexico
Endolumik introduces the FDA-approved Gastric Calibration Tube at San Juan Regional Medical Center for New Mexico's first fluorescent-guided bariatric surgery. Dr. Philip Ernest praises its pivotal role in improving safety and visualization in robotic procedures, aligning with the hospital's tech-driven safety initiatives. Invented by Dr. Nova Szoka, the device addresses safety and performance concerns, reflecting a collaborative push to expand access to advanced bariatric solutions. - November 27, 2023 - Endolumik, Inc.
Marianne K. Henderson, MS PMP, Senior Advisor at the U.S. National Cancer Institute, NIH, Joins CloudLIMS’ Scientific Advisory Board
CloudLIMS is pleased to announce that Marianne K. Henderson, MS PMP, Senior Advisor at the U.S. National Cancer Institute, NIH, has joined CloudLIMS’ Scientific Advisory Board (SAB). - November 17, 2023 - CloudLIMS
Announcing the Recipients of the 2024 Wisconsin Titan 100
Titan CEO and headline sponsor Wipfli LLP are pleased to announce Ms. Ayla Annac, CEO/President of InvivoSciences, Inc. as a 2024 Wisconsin Titan 100. The Titan 100 program recognizes Wisconsin’s Top 100 CEO’s & C-level executives. They are the area’s most accomplished... - November 08, 2023 - InvivoSciences
Creative Diagnostics Launches Carbamazepine Test Reagents
Creative Diagnostics has announced the release of its new line of Carbamazepine Test Reagents. - November 04, 2023 - Creative Diagnostics
Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has launched a range of antibodies, antigens and kits against CLDN6 to support researchers worldwide in preclinical and clinical safety/efficacy testing. CLDN6 may be involved in the development and... - November 04, 2023 - Creative Diagnostics
Creative Biolabs Unveils ADC Services, Igniting Excitement in the Biotech Industry
Creative Biolabs, a prominent provider of groundbreaking biotechnology solutions, proudly announced the expansion of its antibody-drug conjugate (ADC) business with the introduction of novel services. In response to the escalating demand for precision therapies, ADCs have emerged as a promising... - October 29, 2023 - Creative Biolabs
Thrombolex Announces Significant New Insights from the RESCUE Trial with the BASHIR™ Endovascular Catheter
Thrombolex, Inc., announced never-before-reported major reductions in obstruction in all of the segmental pulmonary arteries (PA), based on independent core lab data analysis of 107 patients from 18 sites in the USA, with acute intermediate-risk pulmonary embolism (PE), using the BASHIR™ Endovascular Catheter and small doses of tPA. The RESCUE trial also showed unsurpassed efficacy and safety in this patient population compared to recently published studies with other FDA-cleared devices. - October 24, 2023 - Thrombolex, Inc.
Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory® Platform Reaches the Unreachable
The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc. (HSGCR), a world leader in conducting clinical trials for Huntington’s disease (HD), today announces that the pilot observational study on their innovative online direct-to-patient... - October 16, 2023 - Huntington Study Group
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of NALFIA. - October 15, 2023 - Creative Diagnostics
NuvOx Therapeutics Wins Most Fundable Company by Pepperdine Graziadio Business School
NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the Pepperdine Graziadio Business School's sixth annual Most Fundable Companies® List. NuvOx Therapeutics competed against over 3,000 of early-stage US companies to be named one of 17 companies in total. - October 11, 2023 - NuvOx Therapeutics
Mark A. Cline, of Cline Realtor Group, Embarks on a Journey to Transform Lives with Asea Redox
Asea Redox is a pioneering company that specializes in cellular health and wellness products. By harnessing the power of redox signaling molecules, Asea Redox offers innovative solutions that support optimal cellular communication and regeneration, ultimately leading to improved overall well-being. - September 28, 2023 - Cline Realtor Group
NuvOx Closed Oversubscribed Convertible Notes
NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round, raising approximately $7M out of the originally planned $5M. In this raise, NuvOx leverages large angel groups nationwide, and 11 angel groups joined the round. As a result, NuvOx... - September 27, 2023 - NuvOx Therapeutics
Code Tenderloin & Renegade.Health Continues to Expand Partnership Between East Bay and San Francisco to Address Social Determinants During Sexual Health Awareness Month
Code Tenderloin and Renegade.Health is expanding its partnership with Renegade.Health during Sexual Health Awareness Month with at-home testing kits for STIs with partner organizations in the Tenderloin and throughout San Francisco communities. - September 26, 2023 - Code Tenderloin
Hemanext Inc. Announces Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food and Drug Administration (FDA). - September 21, 2023 - Hemanext
Nanocellect Biomedical Welcomes Peter Vander Horn as Senior VP of Research & Development
NanoCellect Biomedical, a leading pioneer in gentle microfluidic cell sorting technologies, is thrilled to announce the addition of Peter Vander Horn, PhD. to their executive team as Senior Vice President of Research & Development. With an illustrious career marked by groundbreaking... - September 19, 2023 - NanoCellect Biomedical
Hemanext Announces Founder Martin Cannon's Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a significant turning point in its history as the company announces the retirement of its founder, Martin Cannon. Simultaneously, the Hemanext Board of Directors has appointed Andrew Dunham, the... - September 18, 2023 - Hemanext
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research
Creative Diagnostics has announced a series of new ELISA Kits to assist researchers in studing the mechanisms of autoimmunity. - September 06, 2023 - Creative Diagnostics
NuvOx Announces Publication of Research Article in Cancer Research Communication
NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme” in Cancer Research Communications. https://aacrjournals.org/cancerrescommun/article/3/8/1607/728499. Evan Unger, MD, President and CEO of NuvOx,... - September 01, 2023 - NuvOx Therapeutics
Gateway Recruiting Launches Their First Life Sciences Marketing Salary Survey
Gateway Recruiting has launched a salary survey for Marketing professionals in Medical Device, Biotech, and Pharma sectors. Running from August 21st to October 6th, 2023, the survey aims to provide insights into compensation trends, internal equity, and industry changes, with participants receiving a complimentary report. - August 25, 2023 - Gateway Recruiting
Real People Discover the Wellness Power of the Balance Tee at 110 Fitness in Rockland, MA
The New Biotech Balance Tee's Value is Felt During Self-Testing at 110 Fitness on August 15. - August 23, 2023 - BalanceTee.com
Altucell Advances First-Ever Regulatory-Approved Human Islet Cell Encapsulation Therapy for Type 1 Diabetes
Altucell CEO Gary Harlem says this treatment could potentially eradicate the need for insulin and immunosuppressants. - August 22, 2023 - AltuCell Therapeutics
Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease (HD), today shares that the Phase 3 pivotal KINECT®-HD study conducted by HSG in collaboration with Neurocrine Biosciences,... - August 18, 2023 - Huntington Study Group
The FOXG1 Research Foundation Appoints Dr. Soo-Kyung Lee as Chief Scientific Officer to Lead Therapeutics for FOXG1 Syndrome, an Autism-related Rare Disease
The FOXG1 Research Foundation (FRF), a parent-led rare disease patient organization focused on driving therapeutics for FOXG1 syndrome, an Autism-related neurological condition, announced today the appointment of Dr. Soo-Kyung Lee as the new Chief Scientific Officer of the FOXG1 Research Foundation (FRF). Dr. Lee’s dedication to curing FOXG1 syndrome is deeply personal as a mother to Yuna, diagnosed with FOXG1 syndrome in 2009. - August 12, 2023 - FOXG1 Research Foundation
Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates
Creative Diagnostics has announced a series of new reagent solutions to assist researchers in the bioanalysis of ADCs. - August 06, 2023 - Creative Diagnostics
The ALS Therapy Development Institute and Unite Genomics Partner to Integrate Electronic Health Records Into the ALS Research Collaborative
The ALS Therapy Development Institute (ALS TDI) is partnering with Unite Genomics, a leading healthcare data analytics company, to integrate electronic health record (EHR) data into the ALS Research Collaborative (ARC) via Unite Genomics’ state-of-the-art healthcare data access and analytics... - August 02, 2023 - ALS Therapy Development Institute
Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD
HSG Clinical Research, Inc. - the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG) - has begun providing CRO services for CHDI Foundation’s Enroll-HD observational study and clinical research platform in the... - July 25, 2023 - Huntington Study Group
Shark Tank's Kevin Harrington Joins Forces with GARM Clinic
GARM Clinic, a leading provider of Stem Cell Therapies and cutting-edge Regenerative Therapies, is thrilled to announce a groundbreaking partnership with Kevin Harrington, renowned entrepreneur and original "shark" from the hit TV series "Shark Tank." This collaboration marks a... - July 20, 2023 - GARM Clinic
Singapore MedTech Startup Launches Strategic Research Collaboration with Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System
NDR Medical Technology Pioneers Automated Needle Targeting Technology: Strategic Research Collaboration initiated with Clinicians from Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System - July 17, 2023 - NDR Medical Technology
NDR Medical Technology’s ANT-X Granted FDA Clearance, Paving the Way for Image-Guided Surgeries
ANT-X is an interventional robot that leverages C-arm fluoroscopy to help clinicians achieve swift and accurate percutaneous needle placement. NDR Medical Technology, an AI-empowered interventional robotics company, today announced that the ANT-X has been granted FDA 510(k) clearance by the U.S. - July 17, 2023 - NDR Medical Technology
Paras Biopharma (Biologics CDMO) Announces Industry Leading Scale-up Development & Production Process of an “Onco-Immunology Fc-fusion Biologic”
Paras Biopharma (Biologics CDMO) Finland team is pleased to announce that its extensive efforts have resulted in the successful scale-up, optimization & development of a biologically-active onco-immunology, “peptide FC-fusion” biologic. - July 12, 2023 - Paras Biopharmaceuticals Finland Oy
CloudLIMS Exhibits Its Secure Clinical LIMS at the 2023 AACC Annual Scientific Meeting and Clinical Lab Expo
CloudLIMS to showcase its configurable, secure, in-the-cloud Clinical LIMS at booth 4089 during the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo. - July 12, 2023 - CloudLIMS
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics has announced the launch of new reagent solutions for herpesvirus research. - July 07, 2023 - Creative Diagnostics
Hemanext Announces Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region's premier trade association for small to medium-sized companies in the pharmaceutical,... - July 05, 2023 - Hemanext
UserWise, LLC Celebrates Role in Norlase Obtaining 510(k) Clearance and CE Mark Approval
UserWise, LLC, a San Jose-based human factors consultancy, is pleased to announce its instrumental role in obtaining FDA 510(k) clearance and CE Mark approval for the Norlase ECHO™ Green Pattern Laser photocoagulator. UserWise began working with Norlase in 2018 to develop and execute the... - June 23, 2023 - UserWise, LLC
PharmStars Announces Spring 2023 Accelerator Graduates: 13 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces that 13 startups have graduated from its Spring 2023 program focused on “Innovations in Women’s Health or Health Equity.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week program. PharmaU culminated with a Showcase Event, held in Boston in May, that brought together the participating startups and PharmStars’ innovation-minded pharma members. - June 20, 2023 - PharmStars
SunMed Selected to Exhibit SolidAIRity Flex® Oral Endotracheal Tube Stabilization Device at Vizient Innovative Technology Exchange
SunMed has been selected to exhibit the SolidAIRity Flex® Oral Endotracheal Tube Stabilization Device at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine,... - June 10, 2023 - Securisyn Medical
NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it enrolled and treated the first subject in the Phase IIb RESTORE Trial for newly-diagnosed glioblastoma multiforme... - June 09, 2023 - NuvOx Therapeutics
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases
Creative Diagnostics has launched a set of highly specific antibodies against FXIIIa/F13A1 for vascular diseases. - June 09, 2023 - Creative Diagnostics
Opening New Frontiers in Oral Care and the Cannabinoid Market
A groundbreaking patent has been unveiled, presenting a revolutionary method for the prevention and treatment of dental pulp-associated diseases using a cannabinoid-based composition. This patent offers pharmaceutical companies a unique opportunity to enter the rapidly growing cannabinoid market while addressing critical dental care needs. - June 04, 2023 - CannIBite
New Research Benchmarks Biopharmaceutical Perceptions of Global CRO Thought Leadership
Landmark Research Analyzes Perspectives of US and EU Biopharma C-Suite, Clinical Operations and Medical/Regulatory Affairs Professionals on Global CRO Thought Leadership. - June 01, 2023 - Life Science Strategy Group, LLC
Hemanext Continues European Rollout of Hemanext ONE® RBC Processing and Storage System
Groundbreaking technology to be deployed to transfuse thalassemia patients in Italy and acute bleeding burn patients in Norway. - May 25, 2023 - Hemanext
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease in The Lancet Neurology. - Statistically Significant Improvement in Chorea Associated with Huntington’s Disease... - May 19, 2023 - Huntington Study Group